EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Silico Discovery of Cefoperazone as a Novel MMP-2 Inhibitor for Ovarian Cancer Therapy

Fariha Javaid, Sawaira Asim, Fariha Irshad, Nadia Mustafa, Emama Asif, Aroosa Akram, Masooma Ali, Tuba Farhat, Basmala Eslam

Scientific Inquiry and Review · 27.06.2025 · 9 (2) · 64-84

DOI: 10.32350/sir.92.04 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scientific Inquiry and Review, online erschienen am 27.06.2025. Verfasst von Fariha Javaid und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In silico drug repurposing is a promising methodology to identify novel therapeutic applications for existing pharmaceuticals. This study explored the potential of eight third-generation cephalosporin antibiotics as matrix metalloproteinase-2 (MMP-2) allosteric inhibitors for selective targeting in ovarian cancer. MMP-2 is recognized for its pivotal role in tumor progression and metastasis, rendering it a compelling target for oncological treatment. We assessed the binding affinity and stability of selected cephalosporins with MMP-2 using molecular docking and molecular dynamics simulations. Our findings indicate that only Cefoperazone demonstrates robust binding interactions (ΔG -8.1 Kcal/mol) within the active site of MMP-2, suggesting its viability as an effective inhibitor. Molecular dynamics (MD) simulations using normal mode analysis (NMA) further revealed that the Cefoperazone-MMP-2 complex is exceptionally stable under virtual physiological conditions. Complex stability was supported by a low B-factor and a minimal eigenvalue (1.51×10−4). Elastic network model analysis indicated proper molecular mobility close to the binding site, with atoms connected by flexible springs. Consequently, these findings offer novel insights into cefoperazone as a potential candidate for MMP-2 inhibition in the treatment of ovarian cancer. This research validates in silico methodologies for drug repurposing and supports the development of targeted therapeutic strategies for ovarian cancer

Zitieren

APA

Javaid, F., Asim, S., Irshad, F., Mustafa, N., Asif, E., Akram, A., Ali, M., Farhat, T., & Eslam, B. (2025). In Silico Discovery of Cefoperazone as a Novel MMP-2 Inhibitor for Ovarian Cancer Therapy. Scientific Inquiry and Review, 9(2), 64-84. https://doi.org/10.32350/sir.92.04

Vancouver

Javaid F, Asim S, Irshad F, Mustafa N, Asif E, Akram A, et al. In Silico Discovery of Cefoperazone as a Novel MMP-2 Inhibitor for Ovarian Cancer Therapy. Scientific Inquiry and Review. 2025;9(2):64-84. doi:10.32350/sir.92.04

BibTeX
@article{Javaid2025,
  author = {Javaid, Fariha and Asim, Sawaira and Irshad, Fariha and Mustafa, Nadia and Asif, Emama and Akram, Aroosa and Ali, Masooma and Farhat, Tuba and Eslam, Basmala},
  title = {In Silico Discovery of Cefoperazone as a Novel MMP-2 Inhibitor for Ovarian Cancer Therapy},
  journal = {Scientific Inquiry and Review},
  year = {2025},
  volume = {9},
  number = {2},
  pages = {64--84},
  doi = {10.32350/sir.92.04}
}
Kostenlos starten →